Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) EBITDA (2022 - 2025)

Historic EBITDA for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • 60 Degrees Pharmaceuticals' EBITDA fell 785.82% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.9 million, marking a year-over-year increase of 28.42%. This contributed to the annual value of -$8.0 million for FY2024, which is 11204.33% down from last year.
  • Latest data reveals that 60 Degrees Pharmaceuticals reported EBITDA of -$2.3 million as of Q3 2025, which was down 785.82% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' EBITDA ranged from a high of $4.2 million in Q3 2023 and a low of -$4.2 million during Q2 2024
  • Its 4-year average for EBITDA is -$1.6 million, with a median of -$2.0 million in 2023.
  • In the last 5 years, 60 Degrees Pharmaceuticals' EBITDA soared by 38773.5% in 2023 and then plummeted by 54240.77% in 2025.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' EBITDA stood at -$1.7 million in 2022, then dropped by 20.37% to -$2.0 million in 2023, then fell by 3.04% to -$2.1 million in 2024, then decreased by 13.29% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$1.6 million for Q2 2025, and -$1.9 million during Q1 2025.